Modulating durability of HIV-1 env specific humoral immunity with a novel TLR7/8 targeted formulation
用新型 TLR7/8 靶向制剂调节 HIV-1 包膜特异性体液免疫的持久性
基本信息
- 批准号:9205089
- 负责人:
- 金额:$ 35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-08-08 至 2019-07-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS VaccinesALVACAcquired Immunodeficiency SyndromeAdjuvantAgonistAntibody ResponseAntigensB cell differentiationB-Lymphocyte SubsetsB-LymphocytesBindingBloodBone MarrowCellsClinicClinicalCommunicable DiseasesCyclic GMPEmulsionsEvaluationFailureFormulationGoalsHIVHIV AntigensHIV Envelope Protein gp120HIV envelope proteinHIV vaccineHIV-1Helper-Inducer T-LymphocyteHousingHumanHumoral ImmunitiesImmune responseImmunityImmunologic MemoryIn VitroInfectious Diseases ResearchIntramuscularLearningLifeLigandsMacacaMacaca mulattaMediatingMolecularMusOilsOutcomePharmacologic SubstancePhase III Clinical TrialsPlasma CellsPlasmablastPolymersPopulationProteinsRecombinantsRecruitment ActivityResearch InstituteRouteSerinusSerologicalSignal TransductionSkinSmallpoxStructure of germinal center of lymph nodeT-LymphocyteTLR4 geneTLR7 geneTimeToll-like receptorsTranslatingTranslationsVaccinatedVaccinationVaccine AdjuvantVaccinesViral VectorVirusWorkYellow Feveraluminum sulfatebasedeep sequencingdesignimprovedinnovationlymph nodesnanoparticlenext generationnonhuman primatenovelnovel vaccinesparticlepathogenprogramsprophylacticprotective effectprotective efficacyreceptorresponsescale upsubcutaneoustranscriptomics
项目摘要
One of the major obstacles to developing a HIV vaccine is defining adjuvants and immunogens that induce
persistent HIV antigen specific systemic and mucosal humoral responses of high magnitude. Our recent
studies evaluating a novel TLR7/8 ligand (3M052) from 3M Pharmaceuticals formulated in biodegradable
synthetic polymer nanoparticles in RMs has for the first time yielded HIV Env specific long-lived plasma cells
(LLPCs) in the macaque bone marrow for close to one year post final vaccination. The presence of LLPCs
correlated significantly with binding, neutralizing and ADCC activity bearing antibody responses that also
persisted at high magnitude for a year. Robust and persistent germinal center, follicular t helper cells and
lymph node resident plasma cells were also observed in draining lymph nodes in these macaques. Finally, the
persistent response was observed to be dependent on the presence of the novel 3M052 adjuvant alone and
combining with a TLR4 agonist did not further enhance immune responses in contrast to our observations in
mice. However, we have faced considerable challenges in translating our in house developed polymer particle
formulations in industrial scale up for human use. Therefore, building on our proof of concept studies, the goal
of the current proposal is to: a) systematically evaluate a clinical formulation (cGMP scalable oil emulsion
based nanoparticle) developed in partnership with 3M pharmaceuticals and the Infectious Disease Research
Institute (IDRI) in its ability to induce these potent Env specific LLPCs in macaques for expedited translation for
use in humans and b) carefully dissect the innate and B cell based molecular mechanisms by which the 3M052
adjuvant is capable of promoting Env specific LLPCs and long lived antibody responses.
开发艾滋病毒疫苗的主要障碍之一是确定可诱导
持续的HIV抗原特异性全身和粘膜高强度体液反应。我们最近
可生物降解3M药物中新型TLR7/8配体(3M052)的评价研究
RMS中的合成聚合物纳米颗粒首次产生了HIV Env特异性长寿命浆细胞
(LLPC)在最后一次接种后近一年的猕猴骨髓中。LLPC的存在
与携带抗体反应的结合、中和和ADCC活性显著相关,这些抗体反应还
持续了一年的高震级。强大而持久的生发中心、滤泡T辅助细胞和
在这些猕猴的引流淋巴结中也观察到了淋巴结浆细胞的存在。最后,
观察到持续反应依赖于新的3M052佐剂的单独存在和
与我们的观察结果相反,与TLR4激动剂联合使用并未进一步增强免疫反应
老鼠。然而,我们在转换我们内部开发的聚合物颗粒方面面临着相当大的挑战
工业中的配方扩大到供人类使用。因此,在我们概念验证研究的基础上,目标是
当前提议的目的是:a)系统评价一种临床制剂(cGMP可缩放油乳剂
基于纳米颗粒)与3M制药公司和传染病研究机构合作开发
研究所(IDRI)有能力在猕猴中诱导这些强大的环境特异性LLPC,以加快翻译速度
在人类中的使用以及b)仔细剖析3M052通过其先天和基于B细胞的分子机制
佐剂能够促进Env特异性LLPC和长寿抗体应答。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sudhir Pai Kasturi其他文献
Cross-presentation: avoiding trafficking chaos?
交叉呈递:避免交通混乱?
- DOI:
10.1038/ni0508-461 - 发表时间:
2008-05-01 - 期刊:
- 影响因子:27.600
- 作者:
Sudhir Pai Kasturi;Bali Pulendran - 通讯作者:
Bali Pulendran
Sudhir Pai Kasturi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sudhir Pai Kasturi', 18)}}的其他基金
Novel nanoparticulate adjuvants to enhance HIV-1 Env specific mucosal antibody responses
新型纳米颗粒佐剂增强 HIV-1 Env 特异性粘膜抗体反应
- 批准号:
10657401 - 财政年份:2019
- 资助金额:
$ 35万 - 项目类别:
Novel nanoparticulate adjuvants to enhance HIV-1 Env specific mucosal antibody responses
新型纳米颗粒佐剂增强 HIV-1 Env 特异性粘膜抗体反应
- 批准号:
10194358 - 财政年份:2019
- 资助金额:
$ 35万 - 项目类别:
Novel nanoparticulate adjuvants to enhance HIV-1 Env specific mucosal antibody responses
新型纳米颗粒佐剂增强 HIV-1 Env 特异性粘膜抗体反应
- 批准号:
10413110 - 财政年份:2019
- 资助金额:
$ 35万 - 项目类别:
相似国自然基金
病毒载体ALVAC介导的炎性小体活化对肠道CD4+TRM分布的影响及机制研究
- 批准号:31970879
- 批准年份:2019
- 资助金额:58.0 万元
- 项目类别:面上项目
相似海外基金
HVTN 042 AVENTIS PATEUR- LIPO-5 AND ALVAC-HIV VACCINES IN HEALTHY, HIV-1 UNIN
HVTN 042 AVENTIS PATEUR-LIPO-5 和 ALVAC-HIV 疫苗用于健康 HIV-1 UNIN
- 批准号:
7731392 - 财政年份:2006
- 资助金额:
$ 35万 - 项目类别:
HVTN 042 AVENTIS PATEUR- LIPO-5 AND ALVAC-HIV VACCINES IN HEALTHY, HIV-1 UNIN
HVTN 042 AVENTIS PATEUR-LIPO-5 和 ALVAC-HIV 疫苗用于健康 HIV-1 UNIN
- 批准号:
7605567 - 财政年份:2006
- 资助金额:
$ 35万 - 项目类别:
IMMUNIZATION STRATEGY WITH ALVAC-HIV VCP1452 IN HIV-1 SUBJECTS
HIV-1 受试者中 ALVAC-HIV VCP1452 的免疫策略
- 批准号:
7377418 - 财政年份:2005
- 资助金额:
$ 35万 - 项目类别:
INTERMITTENT WITHDRAWAL OF ANTIRETROVIRAL THERAPY-IMMUNIZATION WITH ALVAC-HIV
间歇性停止抗逆转录病毒治疗-使用 ALVAC-HIV 进行免疫接种
- 批准号:
7379067 - 财政年份:2005
- 资助金额:
$ 35万 - 项目类别:
PHASE I/II STUDY OF ALVAC HIV VACCINE IN CHILDREN
儿童 ALVAC HIV 疫苗的 I/II 期研究
- 批准号:
7204833 - 财政年份:2005
- 资助金额:
$ 35万 - 项目类别:
HVTN 042 AVENTIS PATEUR- LIPO-5 AND ALVAC-HIV VACCINES IN HEALTHY, HIV-1 UNIN
HVTN 042 AVENTIS PATEUR-LIPO-5 和 ALVAC-HIV 疫苗用于健康 HIV-1 UNIN
- 批准号:
7375641 - 财政年份:2005
- 资助金额:
$ 35万 - 项目类别:
PACTG 326: ALVAC HIV VACCINES AND AIDSVAX B/B IN CHILDREN BORN TO HIV MOTHERS
PACTG 326:ALVAC HIV 疫苗和艾滋病 VAX B/B 用于艾滋病毒母亲所生的孩子
- 批准号:
7207785 - 财政年份:2005
- 资助金额:
$ 35万 - 项目类别:
INTERMITTENT WITHDRAWAL OF ANTIRETROVIRAL THERAPY-IMMUNIZATION WITH ALVAC-HIV
间歇性停止抗逆转录病毒治疗-使用 ALVAC-HIV 进行免疫接种
- 批准号:
7205768 - 财政年份:2005
- 资助金额:
$ 35万 - 项目类别:
TRIAL TO EVALUATE HIGH DOSE LIVE RECOMBINANT CANARYPOX ALVAC VACCINE (VCP1452)
评估高剂量重组金丝雀痘 ALVAC 活疫苗 (VCP1452) 的试验
- 批准号:
7200079 - 财政年份:2005
- 资助金额:
$ 35万 - 项目类别:
HVTN 042 AVENTIS PATEUR- LIPO-5 AND ALVAC-HIV VACCINES IN HEALTHY, HIV-1 UNIN
HVTN 042 AVENTIS PATEUR-LIPO-5 和 ALVAC-HIV 疫苗用于健康 HIV-1 UNIN
- 批准号:
7207300 - 财政年份:2004
- 资助金额:
$ 35万 - 项目类别: